Cresset Asset Management’s LumiraDx Limited Warrant LMDXW Stock Holding History

Cresset Asset Management’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-27,000	Closed	-$232	–	2009
2023 Q4	$232	Buy	+27,000	New	+$400	﹤0.01%	1837
2023 Q3	–	Sell	-27,000	Closed	-$408	–	2006
2023 Q2	$408	Hold	27,000	–	–	﹤0.01%	1898
2023 Q1	$1.62K	Hold	27,000	–	–	﹤0.01%	813
2022 Q4	$3	Hold	27,000	–	–	﹤0.01%	735
2022 Q3	$3K	Hold	27,000	–	–	﹤0.01%	880
2022 Q2	$24K	Buy	+27,000	New	+$23.3K	﹤0.01%	925

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Cresset Asset Management's LMDXW Position: Q1 2024 in Review

Cresset Asset Management sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2024, closing a stake of 27,000 shares — an estimated $232 sold.

Cresset Asset Management first reported a position in LMDXW in Q2 2022 and held it in 6 quarters. The position peaked at $24K in Q2 2022. 4 funds tracked by Wall St. Rank hold LMDXW as of Q1 2024.

Cresset Asset Management reported no remaining LumiraDx Limited Warrant position as of Q1 2024 after selling out during the quarter.
Cresset Asset Management sold 27,000 LumiraDx Limited Warrant shares in Q1 2024, an estimated $232.
Cresset Asset Management first reported a position in LumiraDx Limited Warrant in Q2 2022 and held it in 6 quarters.
Cresset Asset Management's LumiraDx Limited Warrant position peaked at $24K in Q2 2022.
4 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2024.

Based on Cresset Asset Management's 13F filing for Q1 2024, filed 15 May 2024.